Chimerix (CMRX) to Release Quarterly Earnings on Thursday

Chimerix (NASDAQ:CMRX) will announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.23). The company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $1.26 million. During the same period in the previous year, the firm posted ($0.21) EPS. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chimerix Trading Up 3.0 %

Shares of CMRX opened at $1.02 on Wednesday. The firm’s 50-day moving average price is $0.90 and its 200-day moving average price is $0.91. The firm has a market capitalization of $91.43 million, a price-to-earnings ratio of -1.07 and a beta of 1.13. Chimerix has a 1-year low of $0.75 and a 1-year high of $1.30.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CMRX shares. StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Wedbush reaffirmed an “outperform” rating and set a $6.00 target price on shares of Chimerix in a research note on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research note on Wednesday, August 14th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.